Ernesto Sola Sanchez, MD
Endocrinology, Diabetes & Metabolism · Guaynabo, PRNPI 1447511480
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 375 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,920 and has fallen 74.3% since, to $750 in 2025.
Across 375 payments — averaging $33.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Boehringer Ingelheim$2K
- Amgen$2K
- Sanofi-aventis U.S. LLC$930
- Bayer$750
- Novo Nordisk$724
- plus $3K from 21 others
What the payments were for
- Travel & lodging$5094%
- Food & beverage$11,92695%
- Education$600%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 86 | $2,501 |
| Boehringer Ingelheim | 64 | $2,256 |
| Amgen(2 entities) | 32 | $1,836 |
| Sanofi-aventis U.S. LLC | 20 | $930 |
| Bayer | 19 | $750 |
| Novo Nordisk | 36 | $724 |
| Johnson & Johnson | 23 | $622 |
| Eli Lilly Export S.A. Puerto Rico Branch | 22 | $558 |
| Medtronic | 6 | $543 |
| Merck | 16 | $351 |
| Bayer Puerto Rico Inc. | 14 | $271 |
| Abbott | 8 | $163 |
| AbbVie | 2 | $145 |
| Lilly USA, LLC | 1 | $119 |
| Ascensia Diabetes Care US Inc. | 1 | $118 |
| Dexcom, Inc. | 5 | $102 |
| Corcept Therapeutics | 1 | $100 |
| PBG Puerto Rico LLC | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $73 |
| GSK | 2 | $50 |
| Insulet Corporation | 2 | $47 |
| Novartis | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Exact Sciences | 1 | $25 |
| Radius Health, Inc. | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Pfizer Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,494 in reported general payments places this provider in the 80th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 267 | $353,152 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 244 | $257,323 |
| MounjaroTirzepatide | 194 | $216,077 |
| OzempicSemaglutide | 168 | $164,823 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 187 | $162,802 |
| JardianceEmpagliflozin | 95 | $106,130 |
| FarxigaDapagliflozin Propanediol | 94 | $92,938 |
| GlyxambiEmpagliflozin/Linagliptin | 73 | $81,432 |
| Xigduo XrDapaglifloz Propaned/Metformin | 73 | $69,258 |
| SynthroidLevothyroxine Sodium | 539 | $59,163 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 35 | $37,635 |
| SynjardyEmpagliflozin/Metformin Hcl | 37 | $34,447 |
| KerendiaFinerenone | 13 | $17,404 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $16,272 |
| Jentadueto XrLinagliptin/Metformin Hcl | 16 | $15,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Synjardy Xr, Jardiance, Glyxambi, Synjardy | $2,256 | $671,768667 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $119 | $582,735558 claims |
| Novo NordiskOzempic | $724 | $164,823168 claims |
| AstraZenecaFarxiga | $2,501 | $92,93894 claims |
| MerckJanumet Xr, Janumet, Januvia | $351 | $63,64059 claims |
| AbbVieSynthroid | $145 | $59,163539 claims |
| BayerKerendia | $750 | $17,40413 claims |
| Sanofi-aventis U.S. LLCLantus | $930 | $13,463141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Guaynabo
- Enrique Maldonado CorchadoGuaynabo$8K
- Marina Torres TorresGuaynabo$7K
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Milliette Alvarado SantiagoRio Piedras$75K
- Altagracia Alcantara GonzalezBayamon$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.